Chronic Hepatitis C Treatment with New Antiviral Agents

Abstract

Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed. These drugs target specific stages in the HCV life cycle. Phase 3 clinical trials have demonstrated treatment success rates of 90% with these drugs and their combinations, while real world data indicate a rate of 80-90%. In this review, the use of DAA drugs in the treatment of chronic HCV infection is reviewed in detail.

Keywords

• Chronic hepatitis C
• direct acting antivirals